human
immunodefici
viru
hiv
infect
repres
one
major
health
threat
develop
world
costli
treatment
infect
individu
multipl
highli
effici
antihiv
drug
afford
industri
countri
thu
effici
vaccin
strategi
requir
prevent
spread
infect
molecular
biolog
coronavirus
particular
featur
human
coronaviru
hcov
indic
hcov
vaccin
vector
becom
new
class
highli
effici
vaccin
first
receptor
hcov
human
aminopeptidas
n
hapn
express
mainli
human
dendrit
cell
dc
macrophag
indic
target
hcov
vector
profession
antigen
present
cell
achiev
receptormedi
transduct
second
hcov
structur
gene
replac
multipl
transcript
unit
encod
variou
antigen
viruslik
particl
vlp
contain
hcov
vector
rna
abil
transduc
human
dc
mediat
heterolog
gene
express
cell
final
coronaviru
infect
associ
mainli
respiratori
enter
diseas
natur
transmiss
coronavirus
occur
via
mucos
surfac
human
hcov
caus
common
cold
infect
upper
respiratori
tract
hcov
infect
mainli
encount
children
reinfect
occur
frequent
adult
thu
like
preexist
immun
hcov
significantli
impact
vaccin
effici
hcov
vector
use
human
prophylact
vaccin
sever
viral
infect
develop
last
centuri
lead
erad
smallpox
protect
mani
peopl
diseas
measl
rubella
mump
polio
howev
number
diseas
remain
current
vaccin
suboptim
unavail
furthermor
grow
need
develop
therapeut
vaccin
may
boost
specif
immun
respons
persist
virus
human
immunodefici
viru
hiv
critic
first
step
develop
antivir
vaccin
identif
domin
antigen
contribut
differ
stage
infect
ie
initi
replic
site
entri
spread
host
establish
persist
infect
methodolog
identif
antigen
character
immunodomin
epitop
wellestablish
advanc
approach
field
proteom
genom
chakravarti
et
al
howev
major
bottleneck
develop
new
effect
vaccin
deliveri
antigen
cellular
compon
immun
system
initi
protect
antivir
immun
unmatch
capac
dendrit
cell
dc
sampl
antigen
site
pathogen
entri
transport
pathogen
immunogen
compon
secondari
lymphoid
organ
initi
activ
cell
make
ideal
target
cell
antimicrobi
vaccin
steinman
pope
excel
capac
dc
prime
antivir
cell
respons
readili
shown
vitro
ie
dc
activ
larg
number
virusspecif
cell
mix
lymphocyt
cultur
macatonia
et
al
nonac
et
al
import
prerequisit
initi
immun
respons
vivo
transloc
antigen
peripher
site
secondari
lymphoid
organ
zinkernagel
et
al
high
potenc
dc
induc
protect
antivir
immun
noncytopath
lymphocyt
choriomening
viru
lcmv
vivo
shown
studi
dc
present
specif
viral
antigen
reach
secondari
lymphoid
organ
induct
protect
antivir
cell
respons
ludewig
et
al
ludewig
et
al
dcinduc
ctl
respons
develop
rapidli
dcimmun
mice
protect
acut
system
peripher
viral
challeng
ludewig
et
al
likewis
adopt
transfer
dc
puls
inactiv
sever
immunocompromis
mice
reconstitut
human
pbl
result
induct
protect
respons
lapenta
et
al
moreov
vaccin
sivinfect
rhesu
monkey
cellular
dc
vaccin
significantli
suppress
viral
replic
lu
et
al
recent
studi
untreat
infect
individu
reveal
dcbase
vaccin
elicit
potent
immun
respons
immunodefici
virus
human
lu
et
al
efficaci
vaccin
enhanc
optim
activationmatur
dc
achiev
exampl
dc
matur
via
tolllik
receptor
ligand
augment
activ
cytomegalovirusand
hivspecif
cell
respons
vitro
lore
et
al
likewis
effici
variou
vaccin
format
greatli
enhanc
activ
dc
vivo
mediat
via
codeliveri
immunostimulatori
oligonucleotid
sparwass
et
al
ludewig
et
al
bind
heat
shock
protein
cho
et
al
incorpor
dcactiv
chemokin
factor
prolong
dc
surviv
genet
vaccin
shown
enhanc
immun
respons
recombin
rabi
viru
pinto
et
al
hiv
biragyn
et
al
potent
effect
hiv
vaccin
thu
directli
deliv
antigen
dc
induc
activationmatur
prevent
hiv
infect
thorough
knowledg
biolog
hiv
gener
last
two
decad
pave
way
ration
vaccin
design
furthermor
progress
understand
basic
immunolog
mechan
underli
antigen
present
steinman
pope
lymphocyt
traffick
activ
luther
cyster
immunolog
memori
kaech
et
al
instrument
identif
relev
paramet
ensur
induct
protect
antivir
immun
accordingli
effici
hiv
vaccin
induc
longlast
broad
humor
cellular
respons
immunodomin
hiv
antigen
particular
vaccin
target
activ
dc
ii
contain
immunodomin
antigen
recogn
ctl
th
cell
iii
abl
display
antigen
determin
induc
broadli
neutral
antibodi
respons
iv
applic
via
mucos
surfac
hivspecif
ctl
th
cell
respons
ctl
respons
crucial
contribut
control
immunodefici
viru
infect
broad
virusspecif
ctl
respons
found
peripher
blood
hivinfect
human
bett
et
al
addo
et
al
declin
plasma
viral
rna
primari
hiv
infect
associ
appear
hivspecif
ctl
borrow
et
al
koup
et
al
furthermor
transient
vivo
deplet
cell
lead
massiv
increas
viral
load
sivinfect
monkey
wherea
extens
deplet
day
elicit
progress
aidslik
syndrom
jin
et
al
schmitz
et
al
hivspecif
th
cell
detect
infect
individu
pitcher
et
al
howev
yet
clear
whether
cell
extert
direct
antivir
effect
howev
good
correl
function
cell
respons
hiv
rosenberg
et
al
siv
mckay
et
al
clinic
statu
strongli
support
notion
intact
th
cell
respons
instrument
longterm
viru
control
like
mediat
indirectli
stimul
virusspecif
ctl
sinc
patient
develop
cell
respons
hiv
protein
env
gag
nef
bett
et
al
addo
et
al
broadli
applic
vaccin
elicit
immun
respons
least
three
immmunodomin
antigen
broadli
neutral
antibodi
nonneutr
antibodi
direct
viral
protein
appear
earli
hiv
infect
wherea
neutral
antibodi
appear
usual
rather
late
primari
infect
pilgrim
et
al
furthermor
sera
hivinfect
individu
usual
display
weak
neutral
activ
primari
isol
moor
et
al
fact
deplet
b
cell
rhesu
monkey
significantli
delay
appear
neutral
antibodi
impact
earli
viral
clearanc
support
notion
neutral
antibodi
contribut
significantli
initi
hiv
infect
howev
presenc
neutral
antibodi
may
alter
clinic
cours
shiv
infect
macaqu
prevent
peripart
infect
baba
et
al
convent
vaccin
approach
consist
fail
induc
broadli
neutral
antibodi
respons
mcmichael
hank
nevertheless
distinct
monoclon
antibodi
describ
capabl
neutral
broad
rang
differ
hiv
isol
suggest
antibodi
respons
might
induc
adequ
vaccin
strategi
develop
moor
et
al
exampl
alter
immunodomin
pattern
use
envelop
fusion
construct
expos
normal
occlud
conserv
antigen
region
repres
approach
induct
broadli
neutral
antibodi
fout
et
al
altern
strategi
induct
antibodi
inhibit
infect
primari
cell
differ
primari
isol
report
recent
promis
approach
take
advantag
highli
conserv
bind
domain
glycoprotein
neutral
bind
site
effici
block
entri
wide
rang
primari
cell
hovanessian
et
al
mucos
vaccin
hiv
predominantli
transmit
via
mucos
surfac
pope
haas
exampl
siv
rapidli
cross
epitheli
layer
cervic
mucosa
infect
predominantli
dc
cell
spira
et
al
follow
primari
infect
viru
gain
access
lymphoid
organ
establish
persist
infect
cell
macrophag
appear
constant
lowlevel
exposur
viru
via
mucos
surfac
associ
resist
hiv
infect
zhu
et
al
mucos
vaccin
may
block
transmiss
intravagin
intrarect
appli
siv
amara
et
al
belyakov
et
al
veazey
et
al
indic
hiv
vaccin
prevent
earli
stage
infect
elicit
longlast
mucos
immun
although
immunogen
peptid
nake
nucleic
acid
elicit
immun
respons
hiv
antigen
use
viral
vector
repres
superior
strategi
deliv
hiv
antigen
andor
immunostimulatori
cytokin
specif
target
cell
howev
sever
reason
mani
viru
vector
system
still
limit
abil
induc
broad
longlast
antivir
immun
respons
capabl
prevent
hiv
infect
andor
reduc
viral
load
moreov
safeti
dnabas
vector
adenoassoci
retroor
lentivirus
matter
concern
integr
host
cell
genom
dobbelstein
recombin
adenovirus
studi
intens
hiv
vaccin
candid
mainli
produc
high
titer
nevertheless
high
dose
recombin
adenoviru
vector
appli
induc
antivir
immun
respons
probabl
target
antigen
mainli
nonlymphoid
organ
liver
kreb
et
al
contrast
viral
vector
base
dna
virus
use
positivestrand
rna
virusbas
vector
replic
cytoplasm
consid
safe
vector
unlik
sequenc
vector
integr
host
cell
genom
moreov
safeti
well
document
vector
base
wide
use
vaccin
strain
polioviru
crotti
et
al
viruslik
particl
vlp
contain
replicon
rna
devoid
structur
gene
davi
et
al
harvey
et
al
although
vector
abl
target
dc
andor
induc
mucos
immun
clone
capac
gener
restrict
express
multipl
hiv
antigen
andor
immunostimulatori
cytokin
limit
coronavirus
display
number
featur
may
advantag
overcom
limit
therefor
repres
promis
candid
vaccin
vector
coronavirus
envelop
virus
associ
mainli
respiratori
enter
diseas
exampl
human
coronaviru
infect
mucosa
upper
respiratori
tract
caus
common
cold
coronaviru
genom
largest
known
autonom
replic
rna
size
approxim
kb
two
third
positivestrand
genom
encod
replicas
gene
compris
two
larg
open
read
frame
orf
upon
infect
translat
genom
rna
result
synthesi
replicas
geneencod
polyprotein
extens
process
viral
proteinas
lead
format
function
replicas
transcriptas
complex
within
cytoplasm
infect
cell
ziebuhr
et
al
hallmark
coronaviru
genom
express
uniqu
transcript
strategi
strategi
lead
synthesi
multipl
cotermin
subgenom
mrna
encod
mainli
structur
protein
shown
synthesi
subgenom
mrna
involv
discontinu
step
socal
bodi
sequenc
fuse
genom
leader
sequenc
spaan
et
al
fusion
leader
bodi
sequenc
discontinu
transcript
determin
least
part
cisact
element
term
transcript
regulatori
sequenc
tr
also
refer
transcript
associ
sequenc
element
locat
end
genom
variou
proxim
site
correspond
individu
transcript
unit
although
mani
studi
perform
identifi
cisact
sequenc
requir
coronaviru
transcript
exact
border
tr
element
yet
elucid
pasternak
et
al
howev
short
stretch
nucleotid
within
tr
call
core
sequenc
identifi
determin
site
leaderbodi
fusion
coronaviru
subgenom
rna
molecular
biolog
coronavirus
coronavirusbas
vector
current
consid
promis
system
genet
deliv
multipl
heterolog
gene
specif
target
cell
first
coronavirus
positivestrand
rna
virus
replic
cytoplasm
without
dna
intermediari
make
insert
viral
sequenc
host
cell
genom
unlik
second
coronavirus
largest
rna
genom
known
far
therefor
clone
capac
kb
expect
third
coronavirus
display
uniqu
transcript
process
result
synthesi
subgenom
mrna
encod
mainli
structur
gene
gene
encod
third
genom
replac
multipl
heterolog
gene
eg
immunogen
hiv
antigen
andor
immunomodulatori
gene
fourth
receptor
human
murin
coronavirus
hcov
mous
hapat
viru
mhv
express
human
murin
dc
respect
indic
effici
deliveri
ie
receptormedi
uptak
vlp
heterolog
gene
dc
achiev
final
mucos
rout
natur
way
coronaviru
transmiss
establish
revers
genet
system
coronavirus
allow
gener
recombin
coronavirus
thiel
et
al
thiel
et
al
coley
et
al
one
main
advantag
system
clone
fulllength
coronaviru
cdna
amen
sitedirect
mutagenesi
use
vaccinia
virusmedi
homolog
recombin
techniqu
well
establish
proven
repres
effici
precis
nucleotid
level
method
genet
modifi
recombin
coronaviru
cdna
figur
show
one
exampl
demonstr
eas
use
vaccinia
virusmedi
recombin
genet
modifi
coronaviru
cdna
insert
rnastransduct
human
dc
revers
genet
system
avail
possibl
make
use
uniqu
characterist
coronaviru
transcript
develop
coronaviru
express
vector
rational
express
heterolog
gene
use
coronavirusmedi
transcript
insert
transcript
cassett
compris
coronaviru
tr
locat
upstream
gene
interest
coronaviru
genom
minigenom
vector
rna
shown
human
coronaviru
vector
rna
region
least
kb
dispens
discontinu
transcript
thiel
et
al
region
contain
structur
gene
therefor
vector
rna
infecti
could
demonstr
possibl
construct
human
coronaviru
vector
rna
capabl
mediat
express
multipl
heterolog
protein
noteworthi
vector
rna
packag
vlp
structur
protein
express
tran
thiel
et
al
result
indic
coronavirusbas
vector
system
might
use
heterolog
gene
express
especi
longer
multipl
gene
import
consider
viral
vaccin
vector
potenti
effici
deliveri
genet
materi
specif
target
cell
exampl
target
viral
vaccin
vector
dc
highli
desir
order
optim
vaccin
efficaci
import
note
hcov
receptor
human
aminopeptidas
n
hapn
express
high
level
human
dc
summer
et
al
impli
hcov
vlp
could
use
effici
receptormedi
uptak
transduc
cell
could
demonstr
hcov
vlp
use
transduc
immatur
matur
human
dc
thiel
et
al
therefor
new
class
safe
multigen
vector
base
hcov
repres
particularli
promis
tool
genet
deliv
multipl
antigen
immunostimulatori
cytokin
human
dc
order
studi
efficaci
coronavirusbas
vector
vivo
small
anim
model
desir
therefor
first
establish
revers
genet
system
mhv
made
use
vaccinia
viru
clone
vector
stabli
propag
fulllength
cdna
mhv
strain
recombin
virus
obtain
cdna
clone
indistinguish
parent
strain
tissu
cultur
growth
kinet
plaqu
size
rna
synthesi
mhvrelat
diseas
model
mice
coley
et
al
revers
genet
system
mhv
possibl
gener
mhvbase
multigen
vector
resembl
counterpart
like
coronavirus
mhv
mediat
express
multipl
subgenom
mrna
infect
cell
therefor
possibl
use
coronaviru
transcript
mechan
gener
multigen
mhv
vector
furthermor
mhv
one
beststudi
coronavirus
vitro
vivo
mhv
grow
high
titer
tissu
cultur
pfuml
requir
gener
vlp
well
understood
mhv
also
allow
usag
collect
well
character
inbr
transgen
mice
varieti
establish
immunolog
techniqu
indispens
analysi
vectorinduc
immun
respons
final
shown
infect
murin
dc
turner
et
al
therefor
recombin
mhv
vector
context
murin
model
serv
paradigm
develop
evalu
coronaviru
vaccin
vector
import
prerequisit
studi
efficaci
coronaviru
vaccin
vector
avail
vlp
produc
high
titer
therefor
packag
cell
line
must
establish
mediat
express
coronaviru
structur
protein
tran
end
gener
sever
cell
clone
deriv
murin
cell
stabli
express
mhv
structur
protein
e
emcel
clone
analys
express
e
pcr
use
genom
dna
templat
rt
pcr
use
poli
contain
rna
templat
figur
immunofluoresc
microscopi
figur
five
six
cell
clone
found
contain
express
e
noteworthi
two
consider
made
construct
em
cell
line
first
e
gene
cell
line
express
cellular
transcript
two
separ
mrna
minim
possibl
reconstitut
infecti
virus
recombin
mhv
vector
rna
e
gene
mrna
figur
second
order
achiev
high
titer
mhv
vlp
product
decid
use
mous
cell
line
suscept
mhv
infect
stabl
transfect
mhv
e
gene
case
packag
cell
suscept
vlpinfect
expect
spread
mhv
vector
rna
throughout
tissu
cultur
eand
mexpress
cell
line
use
packag
mhv
vector
rna
encod
addit
replicas
gene
cisact
element
requir
replic
mhv
structur
protein
n
nucleocapsid
protein
therefor
gener
prototyp
mhv
vector
design
mhvveca
contain
replicas
gene
cisact
element
requir
replic
structur
protein
immunodomin
ctl
epitop
lcmv
glycoprotein
fusion
protein
green
fluoresc
protein
nucleocapsid
protein
vector
rna
current
use
thoroughli
assess
efficaci
vlp
product
individu
empackag
cell
first
experi
use
mhvveca
rna
transfect
packag
cell
line
clone
show
transduct
cell
yield
green
fluoresc
plaqu
indic
construct
function
ie
replicas
complex
fusion
protein
produc
expect
could
also
observ
syncytia
vectortransfect
packag
cell
suggest
function
cell
fusionmedi
mhv
protein
present
figur
left
panel
importantli
product
mhv
vlp
shown
fact
transfer
supernat
vectortransfect
cell
primari
dc
cultur
lead
gfp
express
target
cell
figur
right
panel
overal
experi
provid
proofofprincipl
gener
mhv
vlp
feasibl
transgen
express
replicationincompet
virus
target
dc
current
process
test
efficaci
mhv
vlp
product
use
differ
cell
clone
order
identifi
best
packag
cell
clone
ii
establish
optim
protocol
high
titer
vlp
product
human
immunodefici
viru
hiv
pandem
approxim
million
peopl
infect
worldwid
million
death
per
year
repres
major
human
health
problem
major
infect
occur
africa
hivinduc
aid
lead
caus
death
among
adult
age
year
region
furthermor
number
infect
develop
countri
india
china
dramat
grow
recent
year
antivir
drug
treatment
increas
life
expect
qualiti
western
countri
expens
medic
usual
access
infect
individu
develop
countri
thu
urgent
need
effici
afford
vaccin
believ
coronavirus
tremend
capabl
tool
deliv
prophylact
therapeut
protein
diseaserelev
target
cell
human
addit
inher
safe
vector
system
offer
opportun
deliv
multipl
protein
combin
immunostimulatori
substanc
primari
goal
outlin
approach
establish
coronaviru
vector
system
valid
small
anim
model
approach
feasibl
effect
commenc
develop
hcov
repliconbas
vlp
encod
sever
hiv
antigen
env
gag
nef
combin
immunostimulatori
molecul
success
establish
packag
strategi
adapt
hcov
system
allow
product
recombin
hcov
vlp
altern
pseudotyp
mhvbase
vlp
display
tropism
human
dc
may
use
studi
safeti
efficaci
vaccin
prepar
test
adequ
nonhuman
primat
model
